X4 Pharmaceuticals Inc. (NASDAQ:XFOR) shares traded -11.82% lower at $1.94 on Wall Street last session.
In accordance with the data, 8 analysts cover X4 Pharmaceuticals Inc. (NASDAQ:XFOR). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $5.00 and a low of $2.60, we find $3.00. Given the previous closing price of $2.20, this indicates a potential upside of 36.36 percent. XFOR stock price is now 63.06% away from the 50-day moving average and 53.19% away from the 200-day moving average. The market capitalization of the company currently stands at $240.33M.
25-cent Stock Takes $11T Commodities Sector Digital
One brilliantly-run technology firm has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. Best of all, this upstart technology firm is currently trading undiscovered — below 25-cents per share — so very, very few investors know about it yet! For investors… it's an early-stage opportunity in a company that's bringing the US$11T global commodities sector straight into the 21st century.
All the details are in the FREE online report you can get here.
It has been rated a hold by 0 analysts and a buy by 8. Brokers who have rated the stock have averaged $3.51 as their price target over the next twelve months.
With the price target of $3, Cantor Fitzgerald recently initiated with Overweight rating for X4 Pharmaceuticals Inc. (NASDAQ: XFOR). On December 12, 2022, Piper Sandler recently initiated its ‘Overweight’ rating on the stock quoting a target price of $3, while ‘Oppenheimer’ rates the stock as ‘Outperform’.
In other news, Mostafa Adam S., Chief Financial Officer sold 52,500 shares of the company’s stock on Mar 10. The stock was sold for $44,100 at an average price of $0.84. Upon completion of the transaction, the Chief Financial Officer now directly owns 93,696 shares in the company, valued at $0.18 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Mar 10, President and CEO Ragan Paula sold 49,678 shares of the business’s stock. A total of $41,730 was realized by selling the stock at an average price of $0.84. This leaves the insider owning 563,537 shares of the company worth $1.09 million. A total of 0.90% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in XFOR stock. A new stake in X4 Pharmaceuticals Inc. shares was purchased by PERCEPTIVE ADVISORS LLC during the first quarter worth $8,818,000. SCOGGIN MANAGEMENT LP invested $941,000 in shares of XFOR during the first quarter. In the first quarter, SIMPLIFY ASSET MANAGEMENT INC. acquired a new stake in X4 Pharmaceuticals Inc. valued at approximately $776,000. SUSQUEHANNA INTERNATIONAL GROUP, LLP acquired a new stake in XFOR for approximately $548,000. VIRTU FINANCIAL LLC purchased a new stake in XFOR valued at around $220,000 in the second quarter. In total, there are 73 active investors with 35.00% ownership of the company’s stock.
During the past 12 months, X4 Pharmaceuticals Inc. has had a low of $0.65 and a high of $2.41. As of last week, the company has a debt-to-equity ratio of 0.63, a current ratio of 5.00, and a quick ratio of 5.00. The fifty day moving average price for XFOR is $1.2090 and a two-hundred day moving average price translates $1.2703 for the stock.
The latest earnings results from X4 Pharmaceuticals Inc. (NASDAQ: XFOR) was released for Mar, 2023. According to the Biotechnology Company, earnings per share came in at -$0.16, beating analysts’ expectations of -$0.22 by 0.06. This compares to -$0.65 EPS in the same period last year. The company reported revenue of $29.3 million for the quarter, compared to $21.27 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 37.78 percent.
X4 Pharmaceuticals Inc.(XFOR) Company Profile
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase Ib clinical trial to treat chronic neutropenia and Waldenström macroglobulinemia. The company is also developing X4P-002, a CXCR4 antagonist for the treatment of brain cancers; and X4P-003, a CXCR4 antagonist for the treatment of CXCR4 disorders and primary immunodeficiencies. It has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.
Leave a Reply